129253-02-7

Basic information

• Product Name: (S)-isoleucine benzyl amide
• Synonyms: (S)-isoleucine benzyl amide
• CAS NO: 129253-02-7
• Molecular Weight: 220.315
• Mol File: 129253-02-7.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: (S)-isoleucine benzyl amide(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-isoleucine benzyl amide(129253-02-7)
• EPA Substance Registry System: (S)-isoleucine benzyl amide(129253-02-7)

Safety Data

• Hazardous Substances Data: 129253-02-7(Hazardous Substances Data)

Upstream product

• 100-46-9 benzylamine 
• 13139-16-7 N-(tert-butyloxycarbonyl)-L-isoleucine 
• 134015-91-1 C₂₁H₂₆N₂O₃ 
• 3391-99-9 N-Z-L-isoleucine N-hydroxysuccinimide ester 
• 3160-59-6 N-Cbz-L-Isoleucine 
• 154128-82-2 Boc-Ile-NHCH₂C₆H₅ 
• 13139-16-7 N-tert-butyloxy-isoleucine 
• 3392-08-3 tert-(butoxycarbonyl)isoleucine succinimidyl ester 

Downstream Products

• 276257-35-3 Boc-Pro-Ile-NHBn 
• 1056671-22-7 (2S,4S,5S)-5-benzylamino-4-hydroxy-2-isopropyl-6-(naphthalen-1-ylmethoxy)-hexanoic acid ((1S,2S)-1-benzylcarbamoyl-2-methylbutyl)-amide trifluoroacetate 
• 1056671-17-0 (2S,4S,5S)-4-hydroxy-2-isopropyl-5-isopropylamino-6-(naphthalen-1-ylmethoxy)-hexanoic acid ((1S,2S)-1-benzylcarbamoyl-2-methylbutyl)-amide trifluoroacetate 
• 1056676-15-3 (2S,4S,5S)-5-azido-6-benzyloxy-4-hydroxy-2-isopropyl-hexanoic acid ((1S,2S)-1-benzylcarbamoyl-2-methyl-butyl)-amide 
• 1056674-98-6 (2S,4S,5S)-5-azido-4-hydroxy-2-isopropyl-6-[3-(3-methoxy-propoxy)-benzyloxy]-hexanoic acid ((1S,2S)-1-benzylcarbamoyl-2-methylbutyl)-amide 
• 1056675-10-5 (2S,4S,5S)-5-azido-4-hydroxy-2-isopropyl-6-(naphthalen-1-ylmethoxy)-hexanoic acid ((1S,2S)-1-benzylcarbamoyl-2-methylbutyl)-amide 
• 1067648-90-1 (2S,4S,5S)-5-amino-6-benzyloxy-4-hydroxy-2-isopropyl-hexanoic acid ((S)-1-benzylcarbamoyl-2-methyl-butyl)-amide 
• 1067648-28-5 N-[(1S,2S,4S)-4-((S)-1-benzylcarbamoyl-2-methyl-butylcarbamoyl)-1-benzyloxymethyl-2-hydroxy-5-methyl-hexyl]-5-(methanesulphonyl-methyl-amino)-N'-((R)-1-phenyl-ethyl)-isophthalamide 
• 1056671-04-5 (2S,4S,5S)-5-amino-4-hydroxy-2-isopropyl-6-[3-(3-methoxy-propoxy)-benzyloxy]-hexanoic acid ((1S,2S)-1-benzylcarbamoyl-2-methylbutyl)-amide trifluoroacetate 
• 1067648-89-8 (2S,4S,5S)-5-azido-6-benzyloxy-4-hydroxy-2-isopropyl-hexanoic acid ((S)-1-benzylcarbamoyl-2-methyl-butyl)-amide 
• 73-32-5 L-isoleucine 
• 126409-47-0 [(1S,2S,4R)-1-Benzyl-4-((S)-1-benzylcarbamoyl-2-methyl-butylcarbamoyl)-2-hydroxy-5-phenyl-pentyl]-carbamic acid tert-butyl ester 
• 276257-38-6 Fmoc-His(Tr)-Ala-(DL)-Ise-Pro-Ile-NHBn 
• 276257-39-7 Dav-His(Tr)-Ala-(DL)-Ise-Pro-Ile-NHBn 

Relevant articles and documents

[...] - Orn (ClCH2NH) - AA - benzylamine, its synthesis, activity and application (by machine translation)

The invention discloses the following formula of 13 for β - Carboline -3 - formyl - Orn (ClCH2 NH) - AA - NHCH2 C6 H5 (In the formula AA is selected from L - Arg, L - Asn, L - Asp, L - Glu, L - Gly, L - Ile, L - Leu, L - Met, L - Phe, L - Pro, L - Thr, L - Trp, L - Val residue), discloses a process for their preparation, discloses their inhibition of tumor cell growth, therefore this invention discloses their use as anti-tumor medicament. (by machine translation)

Mechanistic implications of the enantioselective addition of alkylzinc reagents to aldehydes catalyzed by nickel complexes with α-amino amide ligands

The enantioselective alkylation of aldehydes catalysed by nickel(ii)-complexes derived from α-amino amides was studied by means of density functional theory (DFT) and ONIOM (B3LYP:UFF) calculations. A mechanism was proposed in order to investigate the origin of enantioselectivity. The chirality-determining step for the alkylation was the formation of the intermediate complexes with the involvement of a 5/4/4-fused tricyclic transition state. The predominant products predicted theoretically were of (S)-configuration, in good agreement with experimental observations. The scope of the reaction was examined and high yields and enantioselectivities were observed for the enantioselective addition of Et2Zn and Me2Zn to aromatic and aliphatic aldehydes.

NEW COMPOUNDS

The invention provides compounds of the formula I wherein Q is aryl or heterocyclyl any of which is optionally substituted; Z is O, S, NRa or S(=O)p; Y is NH, NHNH, CH2NH, O, S or S(=O)p; n is 0, 1, 2 or 3; m is 0, 1 or 2; p is 1 or 2; Ra is H or C1-C4alkyl; R1 is hydrogen, C1-C6alkyl, C0-C3alkanediylC3-C7cycloalkyl, C0-C3alkanediylaryl or C0- C3alkanediylheterocyclyl; R2 is hydrogen or C1-C6alkyl; X' is hydrogen, fluoro, hydroxy, amino or C1-C6alkoxy; X" is hydrogen, or when X' is fluoro, then X" may also be fluoro; R3is C1-C6alkyl; R4' is C1-C6alkyl; R4" is H or C1-C6alkyl; or R4' and R4" together with the carbon atom to which they are attached define a C3-C6cycloalkyl; W is C1-C6alkyl, C3-C7cycloalkyl, aryl or heterocyclyl any of which is optionally substituted; or a pharmaceutically acceptable salt, hydrate or N-oxide thereof. The compounds of the invention are inhibitors of aspartyl proteases such as renin and are among other things useful for the treatment of conditions associated with activities of the RAS, such as hypertension, heart failure and renal insufficiency.